OTCPicks.com Stocks to Watch for Monday, January 11th
PLBI, AEN,
ALKN,
BGMO,
LUNA,
MEXP Our Stocks to Watch tomorrow include Proton Laboratories Inc. (OTC:
PLBI), Adeona Pharmaceuticals Inc. (AMEX: AEN), Alkane Inc. (OTC:
ALKN), Bergamo Acquisition Corp. (OTC:
BGMO), Luna Innovations Inc. (Nasdaq:
LUNA) and Marine Exploration Inc. (OTCBB:
MEXP).
PROTON LABORATORIES INCORPORATED (OTC:
PLBI) "Up 316.67% on Friday" Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N1&L41&F=T Proton Laboratories, Inc. engages in design, manufacture, marketing, and sale of functional water systems in the United States. The company`s functional water systems restructure tap water into one type of water that is alkaline in concentration and one type of water that is acidic in concentration. The company also formulates intellectual properties under licensing agreements; supplies consumer products; consults on projects utilizing functional water; and acts as educators on the benefits of functional electrolyzed water. For the residential market, the company markets functional water systems that are used to produce a health-beneficial, alkaline-concentrated drinking water. For the commercial market, the company markets commercial-grade functional water systems that are used in applications ranging from food preparation to hospital disinfection. Markets The company`s products are used in various industries, including corporate agriculture, organic agriculture, food processing, medicine and dentistry, dermatology, heavy industry, mining, environmental clean-up, product formulations, and beverages. Competition The companys major competitor is Hoshizaki U.S.A. Its potential competitors include Sterilox and Johnson and Johnson. History Proton Laboratories, Inc. was founded in 2000.
PLBI News:
January 8 - Proton Laboratories, Inc. Announces the Acquisition of Regenobody S.A.
Proton Laboratories, Inc. (OTC:
PLBI), a Washington corporation, announced the acquisition of Regenobody S.A., a Dominican Republic company involved in some of the latest technologies associated with stem cell regeneration using the patient`s own stem cells. Pursuant to the Agreement, the Company (
PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc.
Armando Casciati, newly elected President of Proton Laboratories, Inc.
stated that the new company will aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. The prior Proton directors have resigned concurrent with the acquisition. More information may be seen at the Company`s website www.regenobody.com.
ADEONA PHARMACEUTALS INCORPORATED (AMEX: AEN) "Up 22.64% on Friday" Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N1&L1&F=T Adeona Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that such conditions may contribute to the progression of debilitating degenerative diseases, including, dry age-related macular degeneration (dry AMD), Alzheimer`s disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis.
AEN News:
January 8 - Adeona Announces Additional $860,000 Grant for Oral Estriol Multiple Sclerosis Clinical Trial Number of Clinical Sites Doubled to Speed Enrollment Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced that the ongoing clinical trial of its Trimesta (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, Director,
UCLA Multiple Sclerosis Program,
UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at sixteen sites in the US and will enroll up to 150 female Multiple Sclerosis (MS) patients.
Investigators will administer Trimesta along with glatimer acetate (Copaxone), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (
NMSS) in partnership with the National MS Society`s Southern California chapter, with support from the National Institutes of Health (NIH).
According to Dr. Voskuhl, "This additional funding has already had a very positive impact on our trial. It has greatly increased the rate of enrollment by supporting the addition of 9 more clinical sites, bringing the total up to 16 sites across the US. We were extremely pleased that our trial was deemed important enough to be supplemented with these additional funds." Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis Trimesta (oral estriol) has previously completed an initial 22-month, single-agent, crossover Phase I/II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with Trimesta. Following a six-month drug holiday during which the patients weren`t on any drug therapies, Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores.
IMPROVEMENT IN COGNITIVE TESTING SCORES During the prior Phase I/II clinical trial, a 14-percent improvement in Paced Auditory Serial Addition Test ("
PASAT") cognitive testing scores (p=0.04) was also observed in the MS patients at six months of therapy.
PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The
PASAT scores were expressed as a mean percent change from baseline and were significantly improved in the relapsing-remitting group.
ABOUT THE TRIMESTA
PHASE II/III STUDY In the current phase II/III study, Trimesta is being given orally once-a-day versus placebo to 150 female relapsing-remitting MS patients in combination with a standard of care background therapy, subcutaneously injected glatimer acetate. The primary endpoint for the study will evaluate effects of the treatment combination on relapse rates at two years with a one year interim analysis using standard clinical measures of MS disability as well as secondary endpoints of magnetic resonance imaging measurements of brain lesion and effects on cognition. The study is approaching 50% enrollment with the rate of enrollment benefiting significantly from the expansion of clinical sites.
ABOUT TRIMESTA Trimesta is an orally active, immunomodulatory and anti-inflammatory molecule which has been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes, but which has never been introduced in North America. Estriol, the active ingredient in Trimesta, is a weak estrogenic-based molecule that is produced in the placenta by women during pregnancy. Estriol is considered to play an important role in the immunologic privilege offered to the fetus during pregnancy, and is also thought to be responsible for the spontaneous remission of Th1-mediated autoimmune diseases of women (such as multiple sclerosis and rheumatoid arthritis) during pregnancy, especially during the third trimester. Adeona has an exclusive worldwide license from
UCLA to issued and pending patents invented by Dr. Voskuhl including U.S. Patent 6,936,599 covering estriol`s use for MS. While currently marketed therapies for MS sell billions of dollars annually, all require frequent injections and currently is no FDA-approved oral therapy for the treatment of MS.
ALKANE INCORPORATED (OTC:
ALKN) "Up 116.67% on Friday" Company Profile:
http://otcpicknews.com/emailmarketer/link.phpM940&N1&L&F=T Alkane, Inc. is dedicated to the development and sales of alternative fuels and additives which reduce the cost of operating and maintaining vehicles. Additional benefits of Alkane, Inc.`s product offerings include positive environmental impact through the reduction of harmful emissions and a lessened U.S. dependence on foreign oil due to a decrease in crude oil dependent diesel fuel consumption.
ALKN News:
October 21 - Dr. Mathew Zuckerman of Alkane, Inc. Receives The Daily Record`s 2009 Maryland Innovator of the Year Award Mathew Zuckerman, Ph.D. of Alkane, Inc. (OTC:
ALKN) ("Alkane") has been selected as a winner of The Daily Record`s 2009 Innovator of the Year Awards.
The Daily Record began the Innovator of the Year Awards in 2002 as a way to recognize Marylanders and Maryland-based companies for their innovative spirit - for creating new products, new programs, new services, or new processes that have helped their companies, industries, or communities.
"I am honored to have been recognized for my work on Alkane`s flagship product, Monster Diesel," said Zuckerman, who is President & CEO of Alkane, as well as Inventor of patent pending technology on which the Monster Diesel product is based. "We have a product that increases diesel fuel`s power and MPG, lowers emissions, winterizes fuel, and reduces engine wear. It`s just a matter of getting the word out to potential users.
This recognition by The Daily Record helps us to do just that." "The Daily Record`s Innovators of the Year have imagination and vision, the ability to see a need and fill it, and the courage to make change happen," says Christopher Eddings, Publisher of The Daily Record. "We applaud Dr. Zuckerman for embodying the innovative spirit." This year, The Daily Record received more than 80 nominations, which are solicited from The Daily Record`s readers, economic development agencies, chambers of commerce, and the business community at large. Nominees are then asked to complete an application which explains their innovation and the impact it has made on Maryland.
A distinguished panel of judges reviewed the applications and selected 25 winners for 2009, including the top Innovator of the Year. The winners were honored on October 14 at a cocktail reception, held at Baltimore`s American Visionary Art Museum. Winners also were profiled in a special magazine that was included in the October 16 issue of The Daily Record.
ABOUT THE DAILY RECORD For 121 years, The Daily Record Company has provided trusted legal and business information to Maryland readers. In addition to the daily newspaper published five days a week, The Daily Record publishes its website, www.mddailyrecord.com, two blogs, On the Record and Eye on Annapolis, and a variety of special publications on topics of interest to Maryland business and legal professionals.
The Daily Record also honors leading Marylanders through events such as Influential Marylanders, Maryland`s Top 100 Women, Leadership in Law and Health Care Heroes. The Daily Record is owned by Dolan Media Company, trading as DM, of Minneapolis, MN.
BERGAMO ACQUISITION CORPORATION (OTC:
BGMO) "Up 100.00% on Friday" Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N1&L1&F=T Bergamo Acquisition Corp., through its wholly owned subsidiary, Bergamo E&A Corp., focuses on the development of clean energy infrastructure projects in Pakistan. The company involves in the construction of mission-critical infrastructure, including clean energy electric plants, solar renewable energy projects, and LED high efficiency lighting projects.
It also provides construction management and facility maintenance services.
In addition, Bergamo Acquisition Corp. engages in wholesale business that focuses on womens urban fashion apparel and accessories comprising recognized brands. The company is headquartered in Henderson, Nevada.
BGMO News:
January 8 - Bergamo Acquisition Corporation Updates Shareholders on Imminent Financing Bergamo Acquisition Corporation (OTC:
BGMO) announced that the Company will have significant news regarding Bergamo`s funding and a key acquisition. The acquisition will be announced on Monday. On Tuesday the Company will fully update investors on all pending financing as previously announced.
Hillard Herzog, CEO of Bergamo, said, I am very excited about Monday`s announcement of our newest acquisition. I know all investors will find that this will be the right acquisition at the right time. I am happy with the progress we have made on the funding and think both of these announcements will please all investors in Bergamo."
LUNA INNOVATIONS INCORPORATED (NASDAQ:
LUNA) "Up 71.76% on Friday" Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N1&L6&F=T Luna Innovations Incorporated develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia. Lunas nanoWorks division, located in Danville, Virginia, is developing pharmaceutical products empowered by nanomaterials with applications in diagnostics and therapeutics. Lunas exclusive carbon nanomaterials offer unique physical, chemical, thermal, magnetic, biological, optical and electronic properties that can be tailored to customer needs.
LUNA News:
December 29 - Luna Strengthens its Position in Nanomedicine Tego Biosciences is acquired by Luna Innovations Luna Innovations Incorporated (Nasdaq:
LUNA) has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials. Tego Biosciences, Inc.
is a wholly owned subsidiary of Arrowhead Research Corporation (Nasdaq:
ARWR). This acquisition integrates the patent assets of the two leading companies and provides Luna a dominant intellectual property portfolio in carbon nanomaterial-based pharmaceuticals.
We are pleased to add Tegos portfolio of intellectual property to enhance our exciting program in nanomedicines, stated Dr. Kent Murphy, Chairman and CEO of Luna Innovations. The acquisition of Tegos fullerene assets for use in pharmaceuticals demonstrates Lunas continued commitment to novel therapeutics using carbon nanomaterials to treat a variety of inflammatory diseases that address significant markets such as arthritis, allergies and asthma. In addition, Lunas technology is being used to improve diagnostic imaging by developing agents targeted to reveal brain cancer and plaque on arterial walls.
With this acquisition, Lunas intellectual property portfolio for carbon nanomaterials now includes seven owned patents, 10 licensed patents and 44 U.S. and foreign applications. In addition, Luna acquired the research programs Tego has sponsored in radiation protection, anti-viral therapies and macular degeneration, the leading cause of blindness in the elderly.
Luna also acquired Tegos license to The Bronx Project (TBP), a program for developing new medicines based on carbon nanomaterials for Parkinsons and other neurodegenerative diseases. As a result of this transaction, Luna and Tego will equally share in the net proceeds from activities related to the TBP license.
Luna has had an ongoing program to identify novel therapeutic candidates based on the unique properties of carbon nanospheres since 2003. These nanospheres, called buckminister fullerenes, must be chemically modified to make them compatible with living tissues. During this work, Luna has made a number of discoveries, funded in part by government contracts and awards.
Lunas business strategy for developing pharmaceutical products is to form partnerships with established companies to underwrite the expensive development programs.
Tego accrued the combined fruits of most of the pioneering research on fullerene therapeutics that have been discovered over the last decade.
Combining these assets with our own discoveries provides Luna with extensive intellectual property covering therapeutics based on carbon nanomaterials, said Dr. Robert Lenk, President of Lunas nanoWorks Division based in Danville, VA. Our combined patent portfolio consists of 61 patents and pending applications covering classes of fullerene derivatives, methods for synthesizing these compounds and treatments for specific diseases. This acquisition strengthens our position in carbon nanomaterial-based nanomedicines and opens additional markets to attract potential partners as we move forward.
MARINE EXPLORATION INCORPORATED (OTC:
MEXP) "Up 47.92% on Friday" Detailed Quote: www.otcpicks.com/quotes/
MEXP.php Marine Exploration, Inc., a development stage company, engages in marine treasure hunting expeditions. It involves in the exploration and recovery of deep-ocean shipwrecks, including the marketing, sale, and distribution of recovered artifacts, replicas, merchandise, and books through various retail and wholesale sales channels. The company was incorporated in 1996 as Jenkon International, Inc. and changed its name to Multimedia K.I.D., Inc. in 1999. Later, it changed its name to
SYCO, Inc. in 2006; and to Marine Exploration, Inc. in 2007. The company is based in Denver, Colorado.
MEXP News:
January 8 - Marine Exploration Announces Dominican Republic Confirms `Great Discovery` of 1690 Shipwreck; Treasures of Incalculable Value Most important find since Captain Kidd`s ship in 2007 Marine Exploration, Inc. (OTCBB:
MEXP) and joint venture partner Hispaniola Ventures, LLC announce the Dominican Republic has confirmed the Company`s recent discovery of a valuable shipwreck from the 1690s. The treasure includes silver coins, gold, pearls and diamond jewelry.
"A great discovery," notes Francis Soto, Technical Director of the Dominican Republic Underwater Heritage Office in a December 29 news story in Underwater Times.
"The most important find in Dominican waters since the discovery of Captain Kidd`s ship Quedagh Merchant in 2007," states Wilfredo Feliz, Director of the Dominican Republic Ministry of Culture Sub-aquatic Patrimony Office in a December 30 news story in Listin Diario.
"Treasure pieces were of incalculable historical value," according to a news story in Underwater Times.
The objects found include silver coins, jewels, gold jewelry with pearls, solid gold ring with diamonds, two hand-held bronze cannons, numerous pistols and cannons, a bell from 1693 with the phrase `Soli Deo Gloria`, guild pewter plates, navigation compasses, plumb lines for measuring depth, a pistol, sword sheaths, ornaments, plates, silverware, sword handles, a device to measure the ship`s speed, and bronze candlesticks.
Burt D. Webber Jr., famed diver that in 1978 discovered the Concepcion in Dominican Republic waters, is currently the onsite Director of Operations aboard the RV Hispaniola treasure salvage vessel. Mr. Webber comments, "This is such an exciting find especially to be able to salvage significant treasures of silver, gold, and valuable artifacts while the Dominican Republic government observers are onboard. My team has recovered only 10% of what`s down there. We have contracted an area from the Dominicans that is literally a treasure trove of sunken vessels from the 16001700s. We expect to explore at least 5 more wrecks in 2010." OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N1&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N1&L=8&F=T.
Disclosure: OTCPicks.com has been compensated two hundred and fifty thousand free trading shares by a third party (TEN Associates, LLC) for
ALKN advertising and promotional services. OTCPicks.com has received forty thousand free trading shares from a third party for
MEXP advertising and promotional services.
See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.
Home
